黑色素沉积过多可能会导致一系列的皮肤病。黑色素的产生是由黑色素细胞进行的,其中酪氨酸酶起着关键作用。在这项工作中,我们鉴定了一系列具有二氢查耳酮骨架和间苯二酚结构的新型酪氨酸酶抑制剂杂化物,它们可以抑制酪氨酸酶活性并减少皮肤中的黑色素含量。化合物11c具有最强的抗酪氨酸酶活性,在纳摩尔浓度范围内显示出 IC 50值,同时具有显着的抗氧化活性和低细胞毒性。此外,在 HPLC 分析和 3D OrbiSIMS 成像可视化支持下的体外渗透测试表明11c具有出色的渗透性. 更重要的是,化合物11c在体内的豚鼠模型中减少了紫外线诱导的皮肤色素沉着中的黑色素含量。这些结果表明,化合物11c可以作为一种很有前途的强效酪氨酸酶抑制剂,用于开发治疗皮肤色素沉着过度的潜在疗法。
A glycoside in which at least two phenolic hydroxyl groups of a compound having at least two phenolic hydroxyl groups in its molecule are glycosidically linked to anomeric carbon atoms of at least two sugar molecules can be prepared with high yield by a method including the step of allowing phenolic hydroxyl groups of a compound having at least two phenolic hydroxyl groups in its molecule to react with sugar molecules each having an acetylated hydroxyl group attached to an anomeric carbon atom in the presence of an organic solvent and an acid catalyst while removing acetic acid formed during the reaction from the reaction system.
A glycoside in which at least two phenolic hydroxyl groups of a compound having at least two phenolic hydroxyl groups in its molecule are glycosidically linked to anomeric carbon atoms of at least two sugar molecules can be prepared with high yield by a method including the step of allowing phenolic hydroxyl groups of a compound having at least two phenolic hydroxyl groups in its molecule to react with sugar molecules each having an acetylated hydroxyl group attached to an anomeric carbon atom in the presence of an organic solvent and an acid catalyst while removing acetic acid formed during the reaction from the reaction system.
Chapman; Stephen, Journal of the Chemical Society, 1925, vol. 127, p. 889
作者:Chapman、Stephen
DOI:——
日期:——
JPH11236328A
申请人:——
公开号:JPH11236328A
公开(公告)日:1999-08-31
MODULATION OF OSTEOCLAST DIFFERENTIATION
申请人:OSTEOBUILD LTD.
公开号:US20150065427A1
公开(公告)日:2015-03-05
Provided are methods for treating a pathological condition associated with unbalanced osteoclast differentiation by providing an AQP-9 modulator. The modulator can be an AQP-9 inhibitor or an AQP-9 inducer. Also provided are methods for modulating osteoclast differentiation, methods for treating pathological conditions associated with unbalanced osteoclast differentiation, as well as pharmaceutical composition including such modulators.